Biotechnology · EXEL

“The decrease in research and development expenses for the six months ended June 30, 2026, as compared to the corresponding prior year period, was primarily related to decreases in clinical trial costs and personnel expenses, partially offset by increases in license and other collaboration costs and manufacturing costs to support our development candidates (presented as part of other development costs).”

EXEL 10-Q · 2026-08-05

“44 Table of Contents The increase in other hematology and oncology net sales for the three and six months ended June 30, 2026 as compared to the corresponding period in 2025 was primarily driven by increased demand of NIKTIMVO, MONJUVI/MINJUVI and ZYNYZ, reflecting continued strong uptake of these products in the U.S. and their entry into new markets outside of the U.S.”

INCY 10-Q · 2026-07-28

“Peterson and her designated recipient will receive: (i) the severance payments and benefits that she is entitled to under the Company’s Change in Control and Severance Benefit Plan (“Plan”); and (ii) an amount in consideration of any unvested stock options and restricted stock units forfeited pursuant to the Plan, in the gross amount of $1,000,000, subject to the terms and conditions set forth in the Separation Agreement, including execution and non-revocation of the Release of Claims attached thereto.”

EXEL 10-Q · 2025-11-04